Update: Nasacort AQ (triamcinolone acetonide) Rx-to-OTC Switch, Update: Risk of Accidental Ingestion of Ocular and Nasal Products by Children, Update: Tamper-Resistant Pseudoephedrine Product Now Available, Update: Risk of Infection with Tap Water Use in Neti Pots, Update: FDA Announces a Change to Recordkeeping of OTC Sales of Methamphetamine Precursors, Disorders Related to Colds and Allergy: Introduction, Colds, Pathophysiology of Colds, Clinical Presentation of Colds, Treatment of Colds, Assessment of Colds: A Case-Based Approach, Patient Counseling for Colds, Evaluation of Patient Outcomes for Colds, Allergic Rhinitis, Pathophysiology of Allergic Rhinitis, Clinical Presentation of Allergic Rhinitis, Treatment of Allergic Rhinitis, Assessment of Allergic Rhinitis: A Case-Based Approach, Patient Counseling for Allergic Rhinitis, Evaluation of Patient Outcomes for Allergic Rhinitis, Key Points for Disorders Related to Colds and Allergic Rhinitis, Patient Education for Colds, Patient Education for Allergic Rhinitis, Case 11-1, Case 11-2, References.
allergic rhinitis; common cold; hypersensitivity.
Update: Flonase (fluticasone propionate) Rx-To-OTC Switch
Content Update for Chapter 11
, “Disorders Related to Colds and Allergy.” Posted September 1, 2014.
On July 23, 2014, the Food and Drug Administration approved Flonase (fluticasone propionate) for over-the-counter (OTC) sales.1
Flonase is an intranasal glucocorticoid used to treat nasal and ocular symptoms caused by allergic rhinitis. The OTC